5 results
Our primary aim is to assess the (cost-)effects of the ACCESS system in the support of exacerbation self-management of patients with COPD.
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
The overall objective of the PRESTO-2 study is to evaluate the implementation of the Stroke Triage App, a decision support tool for individualized prehospital triage of patients with potential stroke.The specific objectives are the following:1)…
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)